BioQ Pharma Receives CE Mark for Third Infusion System
Jan 27, 2021
San Francisco, CA, January 2021: BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced receipt of CE mark approval in the European Union for its OneDose ReadyfusOR Gen2, single-use medication dispenser. The OneDose ReadyfusOR Gen2 is the second generation of the Company’s original OneDose ReadyfusOR infusion system and was developed to further improve patient convenience. The new OneDose ReadyfusOR Gen2 comes in a smaller size and with a significant weight reduction compared to the original product.
The CE Mark approval demonstrates that BioQ’s OneDose ReadyfusOR Gen2 infusion system is fully compliant with the essential requirements of all relevant European Medical Device Directives related to safety and performance. This product can be used to infuse a variety of pharmaceuticals, such as local anesthetics.
Josh Kriesel, President and CEO of BioQ Pharma, commented, “We are delighted to announce that BioQ Pharma has received a CE Mark on a third infusion product in our growing portfolio. We believe that our pharmaceutical partners, customers and patients will appreciate the convenience and simplicity of this unique product configuration.”
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Stada, Cipla, Lee's Pharm, POA Pharma, Lunatus, Taiba, Pharma Mart, Salmaniya Gate, Lenis, and Sophos Biotech, and Avanos Medical.